Implementing a patient-centred and evidence-based intervention to reduce
BEnzodiazepine and sedative-hypnotic use to improve patient SAFEty and quality of care
Benzodiazepine and sedative hypnotics (BSHs) incur significant adverse effects and costs, especially in older adults.
Addressing BSH overuse in older adults is therefore an urgent priority to improve patient safety in Europe. However,
previous attempts did not lead to large-scale reduction in use.
The goal of BE-SAFE is to improve patient safety by addressing knowledge and practice gaps related to the reduction
of BSHs used for sleep difficulties in Europe.
Coordinated by Prof. Anne Spinewine, Université Catholique de Louvain, (BE), project management by tp21.
Duration: 5 years, starting 1 September 2022 - Total funding: approximately € 5.7 million.